Biosimilars are a
prescription for
better health.

In the U.S., Biosimilars could lead to over $130 billion is savings by 2025, and have been used in over 364 million days of patient therapy.

GRx+Biosims 2024

Save the Date for GRx+Biosims 2024

GRx+Biosims™ 2024 is the leading regulatory science and policy event for the U.S. generics and biosimilars industry. Get the latest information directly from Food and Drug Administration experts, understand the latest policy that impacts the industry and gain valuable insights to advance your professional development. Learn More

2023 Generic & Biosimilar Medicines Savings Report

2023 U.S. Generic and Biosimilar Medicines Savings Report

New findings in the 2023 U.S. Generic & Biosimilar Medicines Savings Report show savings for generics and biosimilars continue to grow with $408 billion saved in 2022 for patients, consumers, employers and taxpayers. Representing 90% of Rx filled but less than 18% of spending, generics and biosimilars are an integral part of the U.S. health care system. Read full report.


The Biosimilars Council advocates to increase patient access to lifesaving, affordable biosimilar medicines.

Our members include manufacturers and stakeholders working to develop biosimilar medicines for the U.S. market


Biosimilars approved in the U.S.


Billion in potential savings for patients and payers


Million total days of patient therapy where biosimilars were used


Million incremental days of therapy

The Benefits of Biosimilars

Expanding access to biosimilars has proven successful in driving down the cost of life-saving therapies.

This increases access to needed medications for patients, strengthens our economy and benefits our society.

View resources for:

Biosimilars Timeline

Recent Blogs & Resources

What Patients Are Saying

Expanding access to biosimilars has proven successful in driving down the cost of life-saving therapies.
Helen, 41, Winter Springs, Florida treated her non-Hodgkin lymphoma with a biosimilar

“Because I have an incurable form of non-Hodgkin lymphoma, I know my medication journey will continue. It is nice to know that when I need a biosimilar again, it will be there for me.”

Helen, 41, Florida

Listen to their stories.

You Can Make A Difference

As the role of biosimilar medicines in our health care system continues to grow, it is essential that patients advocate for affordable biosimilars with their lawmakers. Subscribe to the Biosimilars Bulletin and for alerts on policies that affect your access to these life-saving medicines.